{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:17:14Z","timestamp":1783538234649,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jconrel.2018.08.007","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T22:52:39Z","timestamp":1533336759000},"page":"279-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis"],"prefix":"10.1016","volume":"286","author":[{"given":"Rakeshchandra R.","family":"Meka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaprasad H.","family":"Venkatesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0599-1662","authenticated-orcid":false,"given":"Kamal D.","family":"Moudgil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6937","key":"10.1016\/j.jconrel.2018.08.007_bb0005","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.jconrel.2018.08.007_bb0010","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","article-title":"Rheumatoid arthritis. Pathophysiology and implications for therapy","volume":"322","author":"Harris","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"7 Suppl","key":"10.1016\/j.jconrel.2018.08.007_bb0015","first-page":"S136","article-title":"Current therapeutic agents and treatment paradigms for the management of rheumatoid arthritis","volume":"20","author":"Gibofsky","year":"2014","journal-title":"Am. J. Manag. Care"},{"issue":"6","key":"10.1016\/j.jconrel.2018.08.007_bb0020","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"Use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2018.08.007_bb0025","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","article-title":"IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future","volume":"38","author":"Kim","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.08.007_bb0030","article-title":"Cytokine targeting in rheumatoid arthritis","volume":"3","author":"Bui","year":"2018","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2018.08.007_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clim.2011.09.005","article-title":"Towards the next generation of anti-TNF drugs","volume":"141","author":"Sfikakis","year":"2011","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2018.08.007_bb0040","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"16","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2018.08.007_bb0045","first-page":"216","article-title":"Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study","volume":"33","author":"Lampropoulos","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.jconrel.2018.08.007_bb0050","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2018.08.007_bb0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.08.007_bb0060","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"28","key":"10.1016\/j.jconrel.2018.08.007_bb0065","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1002\/adma.201200454","article-title":"Peptides as targeting elements and tissue penetration devices for nanoparticles","volume":"24","author":"Ruoslahti","year":"2012","journal-title":"Adv. Mater."},{"issue":"6","key":"10.1016\/j.jconrel.2018.08.007_bb0070","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1083\/jcb.200910104","article-title":"Targeting of drugs and nanoparticles to tumors","volume":"188","author":"Ruoslahti","year":"2010","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jconrel.2018.08.007_bb0075","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fonc.2013.00216","article-title":"Tumor-penetrating peptides","volume":"3","author":"Teesalu","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2018.08.007_bb0080","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy","volume":"93","author":"Perez-Herrero","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2018.08.007_bb0085","first-page":"61","article-title":"Molecular targeting of liposomal nanoparticles to tumor microenvironment","volume":"8","author":"Zhao","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.08.007_bb0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2016.03.008","article-title":"Tumor penetrating peptides for improved drug delivery","volume":"110\u2013111","author":"Ruoslahti","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2018.08.007_bb0095","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/art.21719","article-title":"Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis","volume":"54","author":"Koning","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.jconrel.2018.08.007_bb0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clim.2014.01.005","article-title":"Targeting fibroblast-like synovial cells at sites of inflammation with peptide targeted liposomes results in inhibition of experimental arthritis","volume":"151","author":"Vanniasinghe","year":"2014","journal-title":"Clin. Immunol."},{"issue":"20","key":"10.1016\/j.jconrel.2018.08.007_bb0105","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.2217\/nnm-2017-0166","article-title":"Folate-conjugated liposomes target and deliver therapeutics to immune cells in a rat model of rheumatoid arthritis","volume":"12","author":"Poh","year":"2017","journal-title":"Nanomedicine"},{"issue":"12","key":"10.1016\/j.jconrel.2018.08.007_bb0110","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1166\/jbn.2015.2170","article-title":"Enhancing methotrexate tolerance with folate tagged liposomes in arthritic mice","volume":"11","author":"Nogueira","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"issue":"4","key":"10.1016\/j.jconrel.2018.08.007_bb0115","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1172\/JCI65907","article-title":"Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice","volume":"123","author":"Look","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"31","key":"10.1016\/j.jconrel.2018.08.007_bb0120","doi-asserted-by":"crossref","first-page":"12857","DOI":"10.1073\/pnas.1103569108","article-title":"Peptides targeting inflamed synovial vasculature attenuate autoimmune arthritis","volume":"108","author":"Yang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.jconrel.2018.08.007_bb0125","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.autrev.2015.08.001","article-title":"IL-27-induced modulation of autoimmunity and its therapeutic potential","volume":"14","author":"Meka","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.jconrel.2018.08.007_bb0130","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1074-7613(02)00324-2","article-title":"IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells","volume":"16","author":"Pflanz","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2018.08.007_bb0135","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-immunol-032414-112134","article-title":"The immunobiology of interleukin-27","volume":"33","author":"Yoshida","year":"2015","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2018.08.007_bb0140","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1074\/jbc.M110.187013","article-title":"Interleukin-27 and interferon-gamma are involved in regulation of autoimmune arthritis","volume":"286","author":"Rajaiah","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.jconrel.2018.08.007_bb0145","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2567.2012.03622.x","article-title":"Interleukin-27 suppresses osteoclastogenesis via induction of interferon-gamma","volume":"137","author":"Park","year":"2012","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.jconrel.2018.08.007_bb0150","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.biomaterials.2013.10.074","article-title":"Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature","volume":"35","author":"Barui","year":"2014","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.jconrel.2018.08.007_bb0155","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/jps.21939","article-title":"Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations","volume":"99","author":"Migliore","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"81","key":"10.1016\/j.jconrel.2018.08.007_bb0160","doi-asserted-by":"crossref","first-page":"77841","DOI":"10.1039\/C6RA07256A","article-title":"Asymmetric cationic lipid based non-viral vectors for an efficient nucleic acid delivery","volume":"6","author":"Meka","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2018.08.007_bb0165","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.2147\/IJN.S147738","article-title":"Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis","volume":"12","author":"Helmy","year":"2017","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"10.1016\/j.jconrel.2018.08.007_bb0170","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clim.2015.01.011","article-title":"Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ","volume":"157","author":"Astry","year":"2015","journal-title":"Clin. Immunol."},{"issue":"7","key":"10.1016\/j.jconrel.2018.08.007_bb0175","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.185.7.1307","article-title":"Diversification of T cell responses to carboxy-terminal determinants within the 65-kD heat-shock protein is involved in regulation of autoimmune arthritis","volume":"185","author":"Moudgil","year":"1997","journal-title":"J. Exp. Med."},{"issue":"17","key":"10.1016\/j.jconrel.2018.08.007_bb0180","doi-asserted-by":"crossref","first-page":"15138","DOI":"10.1074\/jbc.M111.226365","article-title":"Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses","volume":"286","author":"Venkatesha","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2018.08.007_bb0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biomaterials.2017.03.044","article-title":"Dextran sulfate nanoparticles as a theranostic nanomedicine for rheumatoid arthritis","volume":"131","author":"Heo","year":"2017","journal-title":"Biomaterials"},{"issue":"9","key":"10.1016\/j.jconrel.2018.08.007_bb0190","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/12469","article-title":"Anti-cancer activity of targeted pro-apoptotic peptides","volume":"5","author":"Ellerby","year":"1999","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2018.08.007_bb0195","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.nano.2018.04.018","article-title":"In vivo near infrared fluorescence imaging and dynamic quantification of pancreatic metastatic tumors using folic acid conjugated biodegradable mesoporous silica nanoparticles","volume":"14","author":"Li","year":"2018","journal-title":"Nanomedicine"},{"issue":"4","key":"10.1016\/j.jconrel.2018.08.007_bb0200","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/ar3089","article-title":"Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis","volume":"12","author":"Anderson","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2018.08.007_bb0205","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jconrel.2011.03.001","article-title":"Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis","volume":"152","author":"Hofkens","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.08.007_bb0210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/IJN.S25310","article-title":"Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity","volume":"7","author":"Prabhu","year":"2012","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"10.1016\/j.jconrel.2018.08.007_bb0215","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ijpharm.2011.03.025","article-title":"Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis","volume":"416","author":"van den Hoven","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.08.007_bb0220","article-title":"Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes","volume":"06","author":"Zhang","year":"2017","journal-title":"Br. J. Ophthalmol."},{"issue":"7","key":"10.1016\/j.jconrel.2018.08.007_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130442","article-title":"Nano-drugs based on Nano sterically stabilized liposomes for the treatment of inflammatory neurodegenerative diseases","volume":"10","author":"Turjeman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.08.007_bb0230","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neulet.2015.06.049","article-title":"Peptide-functionalized polymeric nanoparticles for active targeting of damaged tissue in animals with experimental autoimmune encephalomyelitis","volume":"602","author":"Fuhrmann","year":"2015","journal-title":"Neurosci. Lett."},{"issue":"12","key":"10.1016\/j.jconrel.2018.08.007_bb0235","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1002\/art.24026","article-title":"Anti-alpha8 integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus","volume":"58","author":"Scindia","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jconrel.2018.08.007_bb0240","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2012.06.022","article-title":"Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation","volume":"164","author":"Gaillard","year":"2012","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2018.08.007_bb0245","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/annrheumdis-2012-201457","article-title":"Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide","volume":"72","author":"Wythe","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jconrel.2018.08.007_bb0250","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.4049\/jimmunol.179.5.3268","article-title":"Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis","volume":"179","author":"Fitzgerald","year":"2007","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2018.08.007_bb0255","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/j.gastro.2013.09.060","article-title":"Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice","volume":"146","author":"Hanson","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jconrel.2018.08.007_bb0260","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"76","author":"Nam","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.jconrel.2018.08.007_bb0265","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1089\/jir.2011.0094","article-title":"A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis","volume":"31","author":"Astry","year":"2011","journal-title":"J. Interf. Cytokine Res."},{"issue":"4","key":"10.1016\/j.jconrel.2018.08.007_bb0270","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrrheum.2012.170","article-title":"Possible roles of IL-12-family cytokines in rheumatoid arthritis","volume":"9","author":"Pope","year":"2013","journal-title":"Nat Rev Rheumatol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918304607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918304607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:39:56Z","timestamp":1759160396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918304607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":54,"alternative-id":["S0168365918304607"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.007","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}